Circulating Metabolome Landscape in Lynch Syndrome

Overview

Journal Cancer Metab

Publisher Biomed Central

Specialty Oncology

Date 2024 Feb 5

PMID 38317210

Authors

Tiina A Jokela

Jari E Karppinen

Minta Karkkainen

Jukka-Pekka Mecklin

Simon Walker

Toni T Seppala

Eija K Laakkonen

Affiliations

Soon will be listed here.

Abstract

Circulating metabolites systemically reflect cellular processes and can modulate the tissue microenvironment in complex ways, potentially impacting cancer initiation processes. Genetic background increases cancer risk in individuals with Lynch syndrome; however, not all carriers develop cancer. Various lifestyle factors can influence Lynch syndrome cancer risk, and lifestyle choices actively shape systemic metabolism, with circulating metabolites potentially serving as the mechanical link between lifestyle and cancer risk. This study aims to characterize the circulating metabolome of Lynch syndrome carriers, shedding light on the energy metabolism status in this cancer predisposition syndrome.This study consists of a three-group cross-sectional analysis to compare the circulating metabolome of cancer-free Lynch syndrome carriers, sporadic colorectal cancer (CRC) patients, and healthy non-carrier controls. We detected elevated levels of circulating cholesterol, lipids, and lipoproteins in LS carriers. Furthermore, we unveiled that Lynch syndrome carriers and CRC patients displayed similar alterations compared to healthy non-carriers in circulating amino acid and ketone body profiles. Overall, cancer-free Lynch syndrome carriers showed a unique circulating metabolome landscape.This study provides valuable insights into the systemic metabolic landscape of Lynch syndrome individuals. The findings hint at shared metabolic patterns between cancer-free Lynch syndrome carriers and CRC patients.

Citing Articles

species are distinctly associated with patients with Lynch syndrome colorectal cancer.

Salim F, Mizutani S, Shiba S, Takamaru H, Yamada M, Nakajima T iScience. 2024; 27(7):110181.

PMID: 38993678 PMC: 11237946. DOI: 10.1016/j.isci.2024.110181.

References

Yang M, Zhu C, Du L, Huang J, Lu J, Yang J . A Metabolomic Signature of Obesity and Risk of Colorectal Cancer: Two Nested Case-Control Studies. Metabolites. 2023; 13(2). PMC: 9965372. DOI: 10.3390/metabo13020234. View

Kelley K . Methods for the behavioral, educational, and social sciences: an R package. Behav Res Methods. 2008; 39(4):979-84. DOI: 10.3758/bf03192993. View

Chu X, Jaeger M, Beumer J, Bakker O, Aguirre-Gamboa R, Oosting M . Integration of metabolomics, genomics, and immune phenotypes reveals the causal roles of metabolites in disease. Genome Biol. 2021; 22(1):198. PMC: 8259168. DOI: 10.1186/s13059-021-02413-z. View

Rothwell J, Besevic J, Dimou N, Breeur M, Murphy N, Jenab M . Circulating amino acid levels and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition and UK Biobank cohorts. BMC Med. 2023; 21(1):80. PMC: 9976469. DOI: 10.1186/s12916-023-02739-4. View

McCoy A, Noel Z, Sparks A, Chilvers M . hagis, an R Package Resource for Pathotype Analysis of Populations Causing Stem and Root Rot of Soybean. Mol Plant Microbe Interact. 2019; 32(12):1574-1576. DOI: 10.1094/MPMI-07-19-0180-A. View

Ritchie S, Wurtz P, Nath A, Abraham G, Havulinna A, Fearnley L . The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection. Cell Syst. 2016; 1(4):293-301. DOI: 10.1016/j.cels.2015.09.007. View

Halimi H, Farjadian S . Cholesterol: An important actor on the cancer immune scene. Front Immunol. 2022; 13:1057546. PMC: 9719946. DOI: 10.3389/fimmu.2022.1057546. View

Thompson B, Spurdle A, Plazzer J, Greenblatt M, Akagi K, Al-Mulla F . Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2013; 46(2):107-115. PMC: 4294709. DOI: 10.1038/ng.2854. View

Seppala T, Pylvanainen K, Evans D, Jarvinen H, Renkonen-Sinisalo L, Bernstein I . Colorectal cancer incidence in carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hered Cancer Clin Pract. 2017; 15:18. PMC: 5635542. DOI: 10.1186/s13053-017-0078-5. View

10.

Gruppen E, Kunutsor S, Kieneker L, van der Vegt B, Connelly M, de Bock G . GlycA, a novel pro-inflammatory glycoprotein biomarker is associated with mortality: results from the PREVEND study and meta-analysis. J Intern Med. 2019; 286(5):596-609. PMC: 6851697. DOI: 10.1111/joim.12953. View

11.

Rashid S, Freitas M, Cucchi D, Bridge G, Yao Z, Gay L . MLH1 deficiency leads to deregulated mitochondrial metabolism. Cell Death Dis. 2019; 10(11):795. PMC: 6805956. DOI: 10.1038/s41419-019-2018-y. View

12.

Yao X, Tian Z . Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control. 2014; 26(2):257-268. DOI: 10.1007/s10552-014-0507-y. View

13.

Feng S, Wang H, Liu J, Aa J, Zhou F, Wang G . Multi-dimensional roles of ketone bodies in cancer biology: Opportunities for cancer therapy. Pharmacol Res. 2019; 150:104500. DOI: 10.1016/j.phrs.2019.104500. View

14.

Fu Y, Zou T, Shen X, Nelson P, Li J, Wu C . Lipid metabolism in cancer progression and therapeutic strategies. MedComm (2020). 2021; 2(1):27-59. PMC: 8491217. DOI: 10.1002/mco2.27. View

15.

Privat M, Radosevic-Robin N, Aubel C, Cayre A, Penault-Llorca F, Marceau G . BRCA1 induces major energetic metabolism reprogramming in breast cancer cells. PLoS One. 2014; 9(7):e102438. PMC: 4092140. DOI: 10.1371/journal.pone.0102438. View

16.

Martinez-Outschoorn U, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti M . Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012; 11(21):3964-71. PMC: 3507492. DOI: 10.4161/cc.22137. View

17.

Yamamoto T, Kawada K, Obama K . Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients. Int J Mol Sci. 2021; 22(15). PMC: 8348168. DOI: 10.3390/ijms22158002. View

18.

Dominguez-Valentin M, Sampson J, Seppala T, Ten Broeke S, Plazzer J, Nakken S . Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2019; 22(1):15-25. PMC: 7371626. DOI: 10.1038/s41436-019-0596-9. View

19.

Soininen P, Kangas A, Wurtz P, Suna T, Ala-Korpela M . Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015; 8(1):192-206. DOI: 10.1161/CIRCGENETICS.114.000216. View

20.

Ding E, Hu F . Cancer and cholesterol: understanding the V-shaped association in patients with diabetes. CMAJ. 2008; 179(5):403-4. PMC: 2518187. DOI: 10.1503/cmaj.081069. View